Skip over navigation
Outline
Indent Level
Color Curly Brackets (indicating CPC extensions to IPC) References Date Revised

CPC
COOPERATIVE PATENT CLASSIFICATION
Collapse
PEPTIDES ( peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D 519/02 ; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G 69/00 ; macromolecular products derived from proteins C08H 1/00 ; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N 15/00 ; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N 33/00 )
NOTE
-
In this subclass, the following terms or expressions are used with the meanings indicated:
- "amino acids" are compounds in which at least one amino group and at least one carboxyl
group are bound to the same carbon skeleton and the nitrogen atom of the amino group may
form part of a ring;
- "normal peptide link" is one between an alpha-amino group of an amino acid and the
carboxyl group - in position 1 - of another alpha-amino acid;
- "abnormal peptide link" is a link where at least one of the linked amino acids is not an
alpha-amino acid or a link formed by at least one carboxyl or amino group being part of
the side chain of a alpha-amino acid;
- "peptides" are compounds containing at least two amino acid units, which are bound
through at least one normal peptide link, including oligopeptides, polypeptides and
proteins, where:
a. "linear peptides" may comprise rings formed through S-S bridges, or through a hydroxy
or a mercapto group of an hydroxy- or mercapto-amino acid and the carboxyl group of
another amino acid, (e.g. peptide lactones) but do not comprise rings which are
formed only through peptide links;
b. "cyclic peptides" are peptides comprising at least one ring formed only through
peptide links; the cyclisation may occur only through normal peptide links or through
abnormal peptide links, e.g. through the 4-amino group of 2,4-diamino-butanoic acid.
Thus, cyclic compounds in which at least one link in the ring is a non-peptide link
are considered as "linear peptides";
- "depsipeptides" are compounds containing a sequence of at least two alpha-amino acids
and at least one alpha-hydroxy carboxylic acid, which are bound through at least one
normal peptide link and ester links, derived from the hydroxy carboxylic acids, where:
a. "linear depsipeptides" may comprise rings formed through S-S bridges, or through an
hydroxy or a mercapto group of an hydroxy- or mercapto-amino acid and the carboxyl
group of another amino- of hydroxy-acid but do not comprise rings formed only through
peptide or ester links derived from hydroxy carboxylic acids,
e.g. Gly-Ala-Gly-OCH2CO2H and Gly-OCH2CO-Ala-Gly are considered as "linear
depsipeptides", but HOCH2CO-Gly-Ala-Gly does not contain an ester link, and is thus
a derivative of Gly-Ala-Gly which is covered by C07K 5/08 ;
b. "cyclic depsipeptides" are peptides containing at least one ring formed only through
peptide or ester links - derived from hydroxy carboxylic acids -,
e.g. Gly-Ala-Gly-OCH2CO.

Fragments of peptides or peptides modified by removal or addition of amino acids, by substitution of amino acids by others, or by combination of these modifications, are classified as the parent peptides. However, fragments of peptides having only four or less amino acids are also classified in group C07K 5/00 .

Peptides prepared by chemical processes and having an amino acid sequence derived from naturally occurring peptides are classified with the natural one.

Peptides prepared by recombinant DNA technology are not classified according to the host, but according to the original peptide expressed, e.g. HIV peptide expressed in E. coli is classified with HIV peptides.

When classifying in this subclass, classification is also made in group B01D 15/08 insofar as subject matter of general interest relating to chromatography is concerned.


WARNING
-
The following IPC groups are not used in the CPC scheme. Subject matter covered by these groups is classified in the following CPC groups:

C07K5/023 covered by C07K 5/0202
C07K5/027 covered by C07K 5/0205
C07K5/03 covered by C07K 5/0207
C07K5/033 covered by C07K 5/021
C07K5/037 covered by C07K 5/0215
C07K5/062 covered by C07K 5/06017
C07K5/065 covered by C07K 5/06078
C07K5/068 covered by C07K 5/06086
C07K5/072 covered by C07K 5/06104
C07K5/075 covered by C07K 5/0613
C07K5/078 covered by C07K 5/06139
C07K5/083 covered by C07K 5/0804
C07K5/087 covered by C07K 5/0812
C07K5/09 covered by C07K 5/0815
C07K5/093 covered by C07K 5/0819
C07K5/097 covered by C07K 5/0821
C07K5/103 covered by C07K 5/1005
C07K5/107 covered by C07K 5/1016
C07K5/11 covered by C07K 5/1019
C07K5/113 covered by C07K 5/1021
C07K5/117 covered by C07K 5/1024
C07K14/185 covered by C07K 14/1816
C07K14/725 covered by C07K 14/705
C07K14/73 covered by C07K 14/70514
C07K14/735 covered by C07K 14/70535
C07K14/74 covered by C07K 14/70539


Collapse
General methods for the preparation of peptides
{
i.e. processes for the organic chemical preparation of peptides or proteins of any length
}
.
{
by transforming the C-terminal amino acid to amides
}
.
{
of peptides containing derivatised side chain amino acids
}
Collapse
.
in solution
{
( C07K 1/003 , C07K 1/006 take precedence )
}
C07K 1/023
. .
{
using racemisation inhibiting agents
}
C07K 1/026
. .
{
by fragment condensation in solution
}
Collapse
.
on carriers
{
( C07K 1/003 , C07K 1/006 take precedence )
}
C07K 1/042
. .
{
characterised by the nature of the carrier
}
. .
{
using devices to improve synthesis, e.g. reactors, special vessels
}
. .
{
Simultaneous synthesis of different peptide species; Peptide libraries
}
Collapse
.
using protecting groups or activating agents
{
( C07K 1/003 , C07K 1/006 take precedence )
}
Collapse
C07K 1/061
. .
{
using protecting groups
}
C07K 1/062
. . .
{
for alpha- or omega-carboxy functions
}
C07K 1/063
. . .
{
for alpha-amino functions
}
C07K 1/064
. . .
{
for omega-amino or -guanidino functions
}
C07K 1/065
. . .
{
for hydroxy functions, not being part of carboxy functions
}
C07K 1/066
. . .
{
for omega-amido functions
}
C07K 1/067
. . .
{
for sulfur-containing functions
}
C07K 1/068
. . .
{
for heterocyclic side chains
}
Collapse
. .
using activating agents
{
( C07K 1/003 , C07K 1/006 take precedence )
}
C07K 1/082
. . .
{
containing phosphorus
}
C07K 1/084
. . .
{
containing nitrogen
}
C07K 1/086
. . .
{
containing sulfur
}
C07K 1/088
. . .
{
containing other elements, e.g. B, Si, As
}
.
using coupling agents
{
( C07K 1/006 takes precedence )
}
Collapse
C07K 1/107
.
by chemical modification of precursor peptides
Collapse
C07K 1/1072
. .
{
by covalent attachment of residues or functional groups
}
C07K 1/1075
. . .
{
by covalent attachment of amino acids or peptide residues
}
. . .
{
by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
}
Collapse
. .
without change of the primary structure
C07K 1/1133
. . .
{
by redox-reactions involving cystein/cystin side chains
}
C07K 1/1136
. . .
{
by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
}
Collapse
.
by hydrolysis
{
i.e. solvolysis in general
}
C07K 1/122
. .
{
Hydrolysis with acids different from HF
}
C07K 1/124
. .
{
Hydrazinolysis
}
C07K 1/126
. .
{
Aminolysis
}
C07K 1/128
. .
{
sequencing
}
.
Labelling of peptides
Collapse
.
Extraction ; Separation ; Purification
C07K 1/145
. .
{
by extraction or solubilisation
}
Collapse
. .
by chromatography
C07K 1/165
. . .
{
mixed-mode chromatography
}
C07K 1/18
. . .
Ion-exchange chromatography
C07K 1/20
. . .
Partition-, reverse-phase or hydrophobic interaction chromatography
C07K 1/22
. . .
Affinity chromatography or related techniques based upon selective absorption processes
Collapse
C07K 1/24
. .
by electrochemical means
Collapse
C07K 1/26
. . .
Electrophoresis
Collapse
C07K 1/28
. . . .
Isoelectric focusing
C07K 1/285
. . . . .
{
multi dimensional electrophoresis
}
Collapse
C07K 1/30
. .
by precipitation
C07K 1/303
. . .
{
by salting out
}
. . .
{
by crystallization
}
NOTE
-
Large single crystals of proteins from solutions are classified in C30B 7/00 for the method and in C30B 29/58 for the crystal

C07K 1/32
. . .
as complexes
C07K 1/34
. .
by filtration, ultrafiltration or reverse osmosis
. .
by a combination of two or more processes of different types
Peptides of undefined number of amino acids ; Derivatives thereof
Collapse
Peptides having up to 20 amino acids in an undefined or only partially defined sequence ; Derivatives thereof
C07K 4/02
.
from viruses
C07K 4/04
.
from bacteria
C07K 4/06
.
from fungi
C07K 4/08
.
from algae ; from lichens
C07K 4/10
.
from plants
C07K 4/12
.
from animals ; from humans
NOTE
-
If no indication to the contrary is given, all amino acids are considered to be in the natural L-form

Collapse
Peptides containing up to four amino acids in a fully defined sequence ; Derivatives thereof
Collapse
.
containing at least one abnormal peptide link
C07K 5/0202
. .
{
containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
}
C07K 5/0205
. .
{
containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
}
C07K 5/0207
. .
{
containing the structure -NH-(X)4-C(=0), e.g. `isosters`, replacing two amino acids
}
C07K 5/021
. .
{
containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K 5/06 to C07K 5/10 , according to the moiety having normal peptide bonds
}
C07K 5/0212
. .
{
containing the structure -N-C-N-C(=0)-, e.g. retro-inverso peptides
}
C07K 5/0215
. .
{
containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
}
. .
{
containing the structure -C(=O)-C-N-C(=O)-N-C-C(=O)-
}
Collapse
C07K 5/022
. .
{
containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
}
C07K 5/0222
. . .
{
with the first amino acid being heterocyclic, e.g. Pro, Trp
}
C07K 5/0225
. .
{
containing the structure -N-C-C(=O)-N-C(=O)-C-N-
}
C07K 5/0227
. .
{
containing the (partial) peptide sequence -Phe-His-NH-(X)2-C(=0)-, e.g. Renin-inhibitors with n = 2 - 6; for n > 6 see C07K 5/06 to C07K 5/10
}
Collapse
.
containing only normal peptide links
NOTE
-
In groups C07K 5/06 to C07K 5/10 the following terms or expressions are used with the meaning indicated:

neutral: amino acids having in the sidechain the same number of amino groups and carboxylic acid groups or derivatives thereof, e.g. Gly;
basic: amino acids having in the sidechain more amino groups than carboxylic acid groups or derivatives thereof, e.g. Arg;
acidic: amino acids having in the sidechain more carboxylic acid groups or derivatives thereof than amino groups, e.g. Asp;
aliphatic: amino acids having only acyclic carbon atoms in the sidechain, e.g. Ala aromatic;
cycloaliphatic: amino acids having a carbocyclic ring in the sidechain, e.g. Phe
heterocyclic: amino acids wherein the sidechain contains or is part of a heteroring, e.g. Pro;
side chain: the R radical in the optionally functionalised amino acid R-CH(NH2)C02H)

Collapse
C07K 5/06
. .
Dipeptides
Collapse
C07K 5/06008
. . .
{
with the first amino acid being neutral
}
Collapse
C07K 5/06017
. . . .
{
and aliphatic
}
C07K 5/06026
. . . . .
{
the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
}
Collapse
C07K 5/06034
. . . . .
{
the side chain containing 2 to 4 carbon atoms
}
C07K 5/06043
. . . . . .
{
Leu-amino acid
}
C07K 5/06052
. . . . . .
{
Val-amino acid
}
Collapse
C07K 5/0606
. . . . .
{
the side chain containing heteroatoms not provided for by C07K 5/06086 to C07K 5/06139 , e.g. Ser, Met, Cys, Thr
}
C07K 5/06069
. . . . . .
{
Ser-amino acid
}
C07K 5/06078
. . . .
{
and aromatic or cycloaliphatic
}
Collapse
C07K 5/06086
. . .
{
with the first amino acid being basic
}
C07K 5/06095
. . . .
{
Arg-amino acid
}
Collapse
C07K 5/06104
. . .
{
with the first amino acid being acidic
}
Collapse
C07K 5/06113
. . . .
{
Asp- or Asn-amino acid
}
Collapse
C07K 5/06121
. . . . .
{
the second amino acid being aromatic or cycloaliphatic
}
. . . . . .
{
Aspartame
}
Collapse
C07K 5/06139
. . .
{
with the first amino acid being heterocyclic
}
C07K 5/06147
. . . .
{
and His-amino acid; Derivatives thereof
}
C07K 5/06156
. . . .
{
and Trp-amino acid; Derivatives thereof
}
C07K 5/06165
. . . .
{
and Pro-amino acid; Derivatives thereof
}
C07K 5/06173
. . . .
{
and Glp-amino acid; Derivatives thereof
}
C07K 5/06182
. . . .
{
and Pristinamycin II; Derivatives thereof
}
C07K 5/06191
. . .
{
containing heteroatoms different from O, S, or N
}
Collapse
C07K 5/08
. .
Tripeptides
Collapse
C07K 5/0802
. . .
{
with the first amino acid being neutral
}
Collapse
C07K 5/0804
. . . .
{
and aliphatic
}
C07K 5/0806
. . . . .
{
the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
}
C07K 5/0808
. . . . .
{
the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
}
C07K 5/081
. . . . .
{
the side chain containing O or S as heteroatoms, e.g. Cys, Ser
}
C07K 5/0812
. . . .
{
and aromatic or cycloaliphatic
}
Collapse
C07K 5/0815
. . .
{
with the first amino acid being basic
}
C07K 5/0817
. . . .
{
the first amino acid being Arg
}
C07K 5/0819
. . .
{
with the first amino acid being acidic
}
Collapse
C07K 5/0821
. . .
{
with the first amino acid being heterocyclic, e.g. His, Pro, Trp
}
C07K 5/0823
. . . .
{
and Pro-amino acid; Derivatives thereof
}
C07K 5/0825
. . . .
{
and Glp-amino acid; Derivatives thereof
}
C07K 5/0827
. . .
{
containing heteroatoms different from O, S, or N
}
Collapse
C07K 5/10
. .
Tetrapeptides
Collapse
C07K 5/1002
. . .
{
with the first amino acid being neutral
}
Collapse
C07K 5/1005
. . . .
{
and aliphatic
}
C07K 5/1008
. . . . .
{
the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
}
C07K 5/101
. . . . .
{
the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
}
C07K 5/1013
. . . . .
{
the side chain containing O or S as heteroatoms, e.g. Cys, Ser
}
C07K 5/1016
. . . .
{
and aromatic or cycloaliphatic
}
C07K 5/1019
. . .
{
with the first amino acid being basic
}
C07K 5/1021
. . .
{
with the first amino acid being acidic
}
C07K 5/1024
. . .
{
with the first amino acid being heterocyclic
}
C07K 5/1027
. . .
{
containing heteroatoms different from O, S, or N
}
Collapse
. .
Cyclic peptides
{
with only normal peptide bonds in the ring
}
NOTE
-
Cyclic peptides containing at least one abnormal peptide link are classified as linear peptides

C07K 5/123
. . .
{
Tripeptides
}
C07K 5/126
. . .
{
Tetrapeptides
}
Collapse
Peptides having 5 to 20 amino acids in a fully defined sequence ; Derivatives thereof
NOTE
-
In this subgroup cyclic compounds related to specific compounds which are classified in a specific group, e.g. C07K 7/062 , are classified in this specific group only

C07K 7/02
.
Linear peptides containing at least one abnormal peptide link
Collapse
C07K 7/04
.
Linear peptides containing only normal peptide links
Collapse
C07K 7/06
. .
having 5 to 11 amino acids
C07K 7/062
. . .
{
Serum thymic factor
}
C07K 7/065
. . .
{
Thymic humoral factor
}
C07K 7/067
. . .
{
Hemoregulatory peptides based on sequence Glp-Glu-Asp-Cys-Lys
}
Collapse
C07K 7/08
. .
having 12 to 20 amino acids ( gastrins C07K 14/595 ; somatostatins C07K 14/655 ; melanotropins C07K 14/68 )
C07K 7/083
. . .
{
Neurotensin
}
C07K 7/086
. . .
{
Bombesin; Related peptides ( having more than 20 amino acids C07K 14/57572 )
}
C07K 7/14
. .
Angiotensins: Related peptides
C07K 7/16
. .
Oxytocins ; Vasopressins ; Related peptides
C07K 7/18
. .
Kallidins ; Bradykinins ; Related peptides
C07K 7/22
. .
{
Tachykinins, e.g.
}
Eledoisins,
{
Substance P
}
; Related peptides
C07K 7/23
. .
Luteinising hormone-releasing hormone (LHRH) ; Related peptides
C07K 7/28
. .
Gramicidins A, B, D ; Related peptides
Collapse
C07K 7/50
.
Cyclic peptides containing at least one abnormal peptide link
C07K 7/52
. .
with only normal peptide links in the ring
Collapse
C07K 7/54
. .
with at least one abnormal peptide link in the ring
Collapse
C07K 7/56
. . .
the cyclisation not occuring through 2,4-diamino-butanoic acid
C07K 7/58
. . . .
Bacitracins ; Related peptides
Collapse
C07K 7/60
. . .
the cyclisation occuring through the 4-amino group of 2,4-diamino-butanoic acid
C07K 7/62
. . . .
Polymyxins ; Related peptides
Collapse
C07K 7/64
.
Cyclic peptides containing only normal peptide links
C07K 7/645
. .
{
Cyclosporins; Related peptides
}
C07K 7/66
. .
Gramicidins S, C ; Tyrocidins A,B,C ; Related peptides
Collapse
Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence ; Derivatives thereof
Collapse
C07K 9/001
.
{
the peptide sequence having less than 12 amino acids and not being part of a ring structure
}
C07K 9/003
. .
{
Peptides being substituted by heterocyclic radicals, e.g. bleomycin, phleomycin
}
C07K 9/005
. .
{
containing within the molecule the substructure with m,n > 0 and m+n > 0, A,B,D,E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides
}
Collapse
C07K 9/006
.
{
the peptide sequence being part of a ring structure
}
C07K 9/008
. .
{
directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
}
Collapse
Depsipeptides having up to 20 amino acids in a fully defined sequence ; Derivatives thereof
C07K 11/02
.
cyclic, e.g. valinomycins
{
Derivatives thereof
}
Collapse
Peptides having more than 20 amino acids ; Gastrins ; Somatostatins ; Melanotropins ; Derivatives thereof
Collapse
.
{
by chemical synthesis
}
. .
{
Peptide-nucleic acids (PNAs)
}
Collapse
.
from viruses
NOTE
-
When classifying in this group, subject-matter related to viral proteins shall be classified by the symbol C07K 14/005 together with (a number of) appropriate indexing codes out of C12N 2710/00-C12N 2795/00

WARNING
-
1. From March 15, 2012 groups C07K 14/01 - C07K 14/19 and subgroups thereof are no longer used for the classification of new documents. 2. Reclassification of the back-file follows the principle outlined in the Note here above

Collapse
C07K 14/01
. .
DNA viruses
C07K 14/015
. . .
Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
C07K 14/02
. . .
Hepadnaviridae, e.g. hepatitis B virus
C07K 14/025
. . .
Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
Collapse
C07K 14/03
. . .
Herpetoviridae, e.g. pseudorabies virus
C07K 14/032
. . . .
{
Pseudorabies virus, i.e. Anjetzky virus
}
C07K 14/035
. . . .
Herpes simplex virus I or II
Collapse
C07K 14/04
. . . .
Varicella-zoster virus
C07K 14/045
. . . . .
Cytomegalovirus
C07K 14/05
. . . .
Epstein-Barr virus
C07K 14/055
. . . .
Marek`s disease virus
C07K 14/06
. . . .
Infectious bovine rhinotracheitis virus
Collapse
C07K 14/065
. . .
Poxviridae, e.g. avipoxvirus
C07K 14/07
. . . .
Vaccinia virus ; Variola virus
C07K 14/075
. . .
Adenoviridae
Collapse
C07K 14/08
. .
RNA viruses
C07K 14/082
. . .
{
Arteriviridae, e.g. EAV, PRRSV
}
Collapse
C07K 14/085
. . .
Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
C07K 14/09
. . . .
Foot-and-mouth disease virus
C07K 14/095
. . . .
Rhinovirus
C07K 14/10
. . . .
Hepatitis A virus
C07K 14/105
. . . .
Poliovirus
C07K 14/11
. . .
Orthomyxoviridae, e.g. influenza virus
Collapse
C07K 14/115
. . .
Paramyxoviridae, e.g. parainfluenza virus
C07K 14/12
. . . .
Mumps virus ; Measles virus
C07K 14/125
. . . .
Newcastle disease virus
C07K 14/13
. . . .
Canine distemper virus
C07K 14/135
. . . .
Respiratory syncytial virus
C07K 14/14
. . .
Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
C07K 14/145
. . .
Rhabdoviridae, e.g. rabies virus, Duvenhage virus, Mokda virus, vesicular stomatitis virus
Collapse
C07K 14/15
. . .
Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
Collapse
C07K 14/155
. . . .
Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
Collapse
C07K 14/16
. . . . .
HIV-1;
{
HIV-2
}
C07K 14/161
. . . . . .
{
gag-pol, e.g. p55, p24/25, p17/18, p7, p6, p66/68, p51/52, p31/34, p32, p40
}
C07K 14/162
. . . . . .
{
env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
}
C07K 14/163
. . . . . .
{
Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx
}
Collapse
C07K 14/165
. . .
Coronaviridae, e.g. avian infectious bronchitis virus
C07K 14/17
. . . .
Porcine transmissible gastroenteritis virus
C07K 14/175
. . .
Bunyaviridae, e.g. California encephalitis virus, Rift valley fever virus, Hantaan virus
Collapse
C07K 14/18
. . .
Togaviridae;
{
Flaviviridae
}
C07K 14/1808
. . . .
{
Alphaviruses or Group A arboviruses, e.g. sindbis, VEE, EEE, WEE, semliki forest virus ( rubella virus C07K 14/19 )
}
Collapse
C07K 14/1816
. . . .
{
Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus ( hog cholera virus ) , border disease virus
}
C07K 14/1825
. . . . .
{
Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
}
C07K 14/1833
. . . . .
{
Hepatitis C; Hepatitis NANB
}
C07K 14/1841
. . . . .
{
Hepatitis G; Hepatitis NANBNCNDNE
}
C07K 14/19
. . . .
Rubella virus
Collapse
C07K 14/195
.
from bacteria
NOTE
-
In groups C07K 14/20 to C07K 14/365 , where appropriate, after the bacteria terminology, the indication of the order (O), family (F) or genus (G) of the bacteria is given in brackets.

C07K 14/20
. .
from Spirochaetales (O), e.g. Treponema, Leptospira
C07K 14/205
. .
from Campylobacter (G)
Collapse
C07K 14/21
. .
from Pseudomonadaceae (F)
C07K 14/212
. . .
{
Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
}
C07K 14/215
. .
from Halobacteriaceae (F)
C07K 14/22
. .
from Neisseriaceae (F)
C07K 14/225
. .
from Alcaligenes (G)
C07K 14/23
. .
from Brucella (G)
C07K 14/235
. .
from Bordetella (G)
Collapse
C07K 14/24
. .
from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
C07K 14/245
. . .
Escherichia (G)
C07K 14/25
. . .
Shigella (G)
C07K 14/255
. . .
Salmonella (G)
C07K 14/26
. . .
Klebsiella (G)
C07K 14/265
. . .
Enterobacter (G)
C07K 14/27
. . .
Erwinia (G)
C07K 14/275
. . .
Hafnia (G)
C07K 14/28
. .
from Vibrionaceae (F)
C07K 14/285
. .
from Pasteurellaceae (F), e.g. Haemophilus influenza
C07K 14/29
. .
from Richettsiales (o)
C07K 14/295
. .
from Chlamydiales (o)
C07K 14/30
. .
from Mycoplasmatales, e.g. Pleuropneumonia-like organisms (PPLO)
Collapse
C07K 14/305
. .
from Micrococcaceae (F)
C07K 14/31
. . .
from Staphylococcus (G)
Collapse
C07K 14/315
. .
from Streptococcus (G), e.g. Enterococci
C07K 14/3153
. . .
{
Streptokinase
}
C07K 14/3156
. . .
{
from Streptococcus pneumoniae (Pneumococcus) ( Streptokinase C07K 14/3153 )
}
Collapse
C07K 14/32
. .
from Bacillus (G)
C07K 14/325
. . .
Bacillus thuringiensis crystal protein (delta-endotoxin)
C07K 14/33
. .
from Clostridium (G)
C07K 14/335
. .
from Lactobacillus (G)
C07K 14/34
. .
from Corynebacterium (G)
C07K 14/345
. .
from Brevibacterium (G)
C07K 14/35
. .
from Mycobacteriaceae (F)
C07K 14/355
. .
from Nocardia (G)
C07K 14/36
. .
from Actinomyces ; from Streptomyces (G)
C07K 14/365
. .
from Actinoplanes (G)
Collapse
C07K 14/37
.
from fungi
C07K 14/375
. .
from Basidiomycetes
C07K 14/38
. .
from Aspergillus
C07K 14/385
. .
from Penicillium
Collapse
C07K 14/39
. .
from yeasts
C07K 14/395
. . .
from Saccharomyces
C07K 14/40
. . .
from Candida
C07K 14/405
.
from algae
C07K 14/41
.
from lichens
Collapse
C07K 14/415
.
from plants
C07K 14/42
. .
Lectins, e.g. concanavalin, phytohaemagglutinin
C07K 14/425
. .
Zeins
C07K 14/43
. .
{
Sweetening agents, e.g.
}
thaumatin,
{
monellin
}
Collapse
.
from animals ; from humans
Collapse
C07K 14/43504
. .
{
from invertebrates
}
C07K 14/43509
. . .
{
from crustaceans
}
Collapse
C07K 14/43513
. . .
{
from arachnidae
}
C07K 14/43518
. . . .
{
from spiders
}
C07K 14/43522
. . . .
{
from scorpions
}
C07K 14/43527
. . . .
{
from ticks
}
C07K 14/43531
. . . .
{
from mites
}
Collapse
C07K 14/43536
. . .
{
from worms
}
Collapse
C07K 14/4354
. . . .
{
from nematodes
}
C07K 14/43545
. . . . .
{
from Caenorhabditis
}
Collapse
C07K 14/4355
. . . .
{
from cestodes
}
C07K 14/43554
. . . . .
{
from Taenia
}
C07K 14/43559
. . . .
{
from trematodes
}
Collapse
C07K 14/43563
. . .
{
from insects
}
C07K 14/43568
. . . .
{
from wasps
}
C07K 14/43572
. . . .
{
from bees
}
Collapse
C07K 14/43577
. . . .
{
from flies
}
C07K 14/43581
. . . . .
{
from Drosophila
}
C07K 14/43586
. . . .
{
from silkworms
}
C07K 14/4359
. . . .
{
from fleas
}
C07K 14/43595
. . .
{
from coelenteratae, e.g. medusae
}
Collapse
C07K 14/44
. .
from protozoa
C07K 14/445
. . .
Plasmodium
C07K 14/45
. . .
Toxoplasma
C07K 14/455
. . .
Eimeria
Collapse
C07K 14/46
. .
from vertebrates
C07K 14/461
. . .
{
from fish
}
C07K 14/463
. . .
{
from amphibians
}
C07K 14/465
. . .
from birds
Collapse
C07K 14/47
. . .
from mammals
Collapse
C07K 14/4701
. . . .
{
not used
}
Collapse
C07K 14/4702
. . . . .
{
Regulators; Modulating activity
}
C07K 14/4703
. . . . . .
{
Inhibitors; Supressors
}
Collapse
C07K 14/4705
. . . . . .
{
stimulating, promoting or activating activity
}
C07K 14/4706
. . . . . . .
{
Guanosine triphosphatase activating protein, GAP
}
Collapse
C07K 14/4707
. . . . .
{
Muscular dystrophy
}
C07K 14/4708
. . . . . .
{
Duchenne dystrophy
}
C07K 14/471
. . . . . .
{
Myotonic dystrophy
}
C07K 14/4711
. . . . .
{
Alzheimer`s disease; Amyloid plaque core protein
}
C07K 14/4712
. . . . .
{
Cystic fibrosis
}
C07K 14/4713
. . . . .
{
Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
}
C07K 14/4715
. . . . .
{
Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
}
C07K 14/4716
. . . . .
{
Muscle proteins, e.g. myosin, actin
}
C07K 14/4717
. . . . .
{
Plasma globulins, lactoglobulin
}
C07K 14/4718
. . . . .
{
Cytokine-induced proteins
}
C07K 14/472
. . . . .
{
Complement proteins, e.g. anaphylatoxin, C3a, C5a
}
C07K 14/4721
. . . . .
{
Lipocortins
}
C07K 14/4722
. . . . .
{
G-proteins
}
C07K 14/4723
. . . . .
{
Cationic antimicrobial peptides, e.g. defensins
}
C07K 14/4725
. . . . .
{
Proteoglycans, e.g. aggreccan
}
C07K 14/4726
. . . . .
{
Lectins
}
C07K 14/4727
. . . . .
{
Mucins, e.g. human intestinal mucin
}
C07K 14/4728
. . . . .
{
Calcium binding proteins, e.g. calmodulin
}
C07K 14/473
. . . . .
{
alpha-Glycoproteins
}
C07K 14/4731
. . . . .
{
Recognins, e.g. malignin
}
C07K 14/4732
. . . . .
{
Casein ( in foodstuffs A23J )
}
C07K 14/4733
. . . . .
{
Acute pancreatitis-associated protein
}
C07K 14/4735
. . . . .
{
Villin
}
C07K 14/4736
. . . . .
{
Retinoblastoma protein
}
C07K 14/4737
. . . . .
{
C-reactive protein
}
C07K 14/4738
. . . . .
{
Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR ( cell cycle dependent kinases C12N 9/12 )
}
C07K 14/474
. . . . .
{
Pancreatic thread protein; Reg protein
}
C07K 14/4741
. . . . .
{
Keratin; Cytokeratin
}
C07K 14/4742
. . . . .
{
Bactericidal/Permeability-increasing protein (BPI)
}
C07K 14/4743
. . . . .
{
Insulin-like growth factor binding protein
}
C07K 14/4745
. . . . .
{
Cancer-associated SCM-recognition factor, CRISPP
}
C07K 14/4746
. . . . .
{
p53
}
C07K 14/4747
. . . . .
{
Apoptosis related proteins
}
C07K 14/4748
. . . . .
{
Tumour specific antigens; Tumour rejection antigen precursors (TRAP), e.g. MAGE
}
Collapse
C07K 14/475
. .
Growth factors ; Growth regulators
C07K 14/4753
. . .
{
Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
}
C07K 14/4756
. . .
{
Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
}
C07K 14/48
. . .
Nerve growth factor (NGF)
C07K 14/485
. . .
Epidermal growth factor (EGF) (urogastrone)
C07K 14/49
. . .
Platelet-derived growth factor (PDGF)
C07K 14/495
. . .
Transforming growth factor (TGF)
Collapse
C07K 14/50
. . .
Fibroblast growth factors (FGF)
C07K 14/501
. . . .
{
acidic FGF (aFGF)
}
C07K 14/503
. . . .
{
basic FGF (bFGF)
}
C07K 14/505
. . .
Erythropoietin (EPO)
C07K 14/51
. . .
Bone morphogenetic factor ; Osteogenins ; Osteogenic factor ; Bone-inducing factor
C07K 14/515
. . .
Angiogenesic factors ; Angiogenin
Collapse
C07K 14/52
. .
Cytokines ; Lymphokines ; Interferons
Collapse
C07K 14/521
. . .
{
Chemokines
}
C07K 14/522
. . . .
{
Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
}
C07K 14/523
. . . .
{
Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
}
C07K 14/524
. . .
{
Thrombopoietin, i.e. C-MPL ligand
}
Collapse
C07K 14/525
. . .
Tumor necrosis factor (TNF)
C07K 14/5255
. . . .
{
Lymphotoxin (LT)
}
Collapse
C07K 14/53
. . .
Colony-stimulating factor (CSF)
C07K 14/535
. . . .
Granulocyte CSF ; Granulocyte-macrophage CSF
Collapse
C07K 14/54
. . .
Interleukins (IL)
C07K 14/5403
. . . .
{
IL-3
}
C07K 14/5406
. . . .
{
IL-4
}
C07K 14/5409
. . . .
{
IL-5
}
C07K 14/5412
. . . .
{
IL-6
}
C07K 14/5415
. . . .
{
Leukaemia inhibitory factor (LIF)
}
C07K 14/5418
. . . .
{
IL-7
}
C07K 14/5421
. . . .
{
IL-8
}
C07K 14/5425
. . . .
{
IL-9
}
C07K 14/5428
. . . .
{
IL-10
}
C07K 14/5431
. . . .
{
IL-11
}
C07K 14/5434
. . . .
{
IL-12
}
C07K 14/5437
. . . .
{
IL-13
}
C07K 14/544
. . . .
{
IL-14
}
C07K 14/5443
. . . .
{
IL-15
}
C07K 14/5446
. . . .
{
IL-16
}
C07K 14/545
. . . .
IL-1
C07K 14/55
. . . .
IL-2
Collapse
C07K 14/555
. . .
Interferons (IFN)
C07K 14/56
. . . .
IFN-alpha
C07K 14/565
. . . .
IFN-beta
C07K 14/57
. . . .
IFN-gamma
Collapse
C07K 14/575
. .
Hormones ( derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K 14/665 , e.g. corticotropin C07K 14/695 )
C07K 14/57509
. . .
{
Corticotropin releasing factor (CRF) (Urotensin)
}
C07K 14/57518
. . .
{
Placental lactogen; Chorionic somatomammotropin
}
C07K 14/57527
. . .
{
Calcitonin gene related peptide
}
C07K 14/57536
. . .
{
Endothelin, vasoactive intestinal contractor (VIC)
}
C07K 14/57545
. . .
{
Neuropeptide Y
}
C07K 14/57554
. . .
{
Prolactin
}
C07K 14/57563
. . .
{
Vasoactive intestinal peptide (VIP); Related peptides
}
C07K 14/57572
. . .
{
Gastrin releasing peptide ( bombesin C07K 7/086 )
}
C07K 14/57581
. . .
{
Thymosin; Related peptides
}
C07K 14/5759
. . .
{
Products of obesity genes, e.g. leptin, obese (OB), tub, fat
}
Collapse
C07K 14/58
. . .
Atrial natriuretic factor complex ; Atriopeptin ; Atrial natriuretic peptide (ANP) ; Cardionatrin ; Cardiodilatin
C07K 14/582
. . . .
{
at least 1 amino acid in D-form
}
Collapse
C07K 14/585
. . .
Calcitonins
C07K 14/5855
. . . .
{
at least 1 amino acid in D-form
}
Collapse
C07K 14/59
. . .
Follicle-stimulating hormone (FSH) ; Chorionic gonadotropins, e.g. HCG ; Luteinising hormone (LH) ; Thyroid-stimulating hormone (TSH)
C07K 14/592
. . . .
{
at least 1 amino acid in D-form
}
Collapse
C07K 14/595
. . .
Gastrins ; Cholecystokinins (CCK)
C07K 14/5955
. . . .
{
at least 1 amino acid in D-form
}
C07K 14/60
. . .
Growth-hormone releasing factors (GH-RF) (Somatoliberin)
C07K 14/605
. . .
Glucagons
Collapse
C07K 14/61
. . .
Growth hormones (GH) (Somatotropin)
C07K 14/615
. . . .
Extraction from natural sources
Collapse
C07K 14/62
. . .
Insulins
C07K 14/622
. . . .
{
at least 1 amino acid in D-form
}
C07K 14/625
. . . .
extraction from natural sources
C07K 14/63
. . .
Motilins
C07K 14/635
. . .
Parathyroid hormone (parathormone) ; Parathyroid hormone-related peptides
C07K 14/64
. . .
Relaxins
C07K 14/645
. . .
Secretins
C07K 14/65
. . .
Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
Collapse
C07K 14/655
. . .
Somatostatins
C07K 14/6555
. . . .
{
at least 1 amino acid in D-form
}
Collapse
C07K 14/66
. . .
Thymopoietins
C07K 14/662
. . . .
{
at least 1 amino acid in D-form
}
Collapse
C07K 14/665
. .
derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
Collapse
C07K 14/67
. . .
Lipotropins, e.g. beta, gamma lipotropin
C07K 14/672
. . . .
{
with at least 1 amino acid in D-form
}
Collapse
C07K 14/675
. . .
beta-Endorphins
C07K 14/6755
. . . .
{
with at least 1 amino acid in D-form
}
Collapse
C07K 14/68
. . .
Melanocyte-stimulating hormone (MSH)
C07K 14/685
. . . .
alpha-Melanotropin
C07K 14/69
. . . .
beta-Melanotropin
Collapse
C07K 14/695
. . .
Corticotropin (ACTH)
C07K 14/6955
. . . .
{
with at least 1 amino acid in D-form
}
Collapse
C07K 14/70
. . .
Enkephalins
C07K 14/702
. . . .
{
with at least 1 amino acid in D-form
}
Collapse
C07K 14/705
. .
Receptors ; Cell surface antigens ; Cell surface determinants
{
( tumour specific antigens C07K 14/4748 )
}
Collapse
C07K 14/70503
. . .
{
Immunoglobulin superfamily
}
C07K 14/70507
. . . .
{
CD2
}
C07K 14/7051
. . . .
{
T-cell receptor (TcR)-CD3 complex
}
C07K 14/70514
. . . .
{
CD4
}
C07K 14/70517
. . . .
{
CD8
}
C07K 14/70521
. . . .
{
CD28, CD152
}
C07K 14/70525
. . . .
{
ICAM molecules, e.g. CD50, CD54, CD102
}
C07K 14/70528
. . . .
{
CD58
}
C07K 14/70532
. . . .
{
B7 molecules, e.g. CD80, CD86
}
C07K 14/70535
. . . .
{
Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
}
C07K 14/70539
. . . .
{
MHC-molecules, e.g. HLA-molecules
}
C07K 14/70542
. . . .
{
CD106
}
Collapse
C07K 14/70546
. . .
{
Integrin superfamily
}
C07K 14/7055
. . . .
{
Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
}
C07K 14/70553
. . . .
{
Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
}
C07K 14/70557
. . . .
{
Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
}
Collapse
C07K 14/7056
. . .
{
Lectin superfamily, e.g. CD23, CD72
}
C07K 14/70564
. . . .
{
Selectins, e.g. CD62
}
C07K 14/70567
. . .
{
Nuclear receptors, e.g. retinoic acid receptor (RAR), RXR, nuclear orphan receptors
}
C07K 14/70571
. . .
{
for neuromediators, e.g. serotonin receptor, dopamine receptor
}
C07K 14/70575
. . .
{
NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 ( NGF C07K 14/48 , TNF C07K 14/525 )
}
C07K 14/70578
. . .
{
NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 ( NGF-receptor C07K 14/71 , TNF-receptor C07K 14/7151 )
}
C07K 14/70582
. . .
{
CD71
}
C07K 14/70585
. . .
{
CD44
}
C07K 14/70589
. . .
{
CD45
}
C07K 14/70592
. . .
{
CD52
}
C07K 14/70596
. . .
{
Molecules with a "CD"-designation not provided for elsewhere
}
C07K 14/71
. . .
for growth factors ; for growth regulators
Collapse
C07K 14/715
. . .
for cytokines ; for lymphokines ; for interferons
C07K 14/7151
. . . .
{
for tumor necrosis factor (TNF), for lymphotoxin (LT)
}
C07K 14/7153
. . . .
{
for colony-stimulating factors (CSF)
}
C07K 14/7155
. . . .
{
for interleukins (IL)
}
C07K 14/7156
. . . .
{
for interferons (IFN)
}
C07K 14/7158
. . . .
{
for chemokines
}
Collapse
C07K 14/72
. . .
for hormones
{
( for neuromediators C07K 14/70571 )
}
C07K 14/721
. . . .
{
Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
}
C07K 14/723
. . . .
{
G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
}
Collapse
C07K 14/745
. .
Blood coagulation or fibrinolysis factors
C07K 14/7455
. . .
{
Thrombomodulin
}
C07K 14/75
. . .
Fibrinogen
C07K 14/755
. . .
Factors VIII,
{
e.g. factor VIII C (AHF), factor VIII Ag (VWF)
}
Collapse
C07K 14/76
. .
Albumins
C07K 14/765
. . .
Serum albumin, e.g. HSA
C07K 14/77
. . .
Ovalbumin
C07K 14/775
. .
Apolipopeptides
C07K 14/78
. .
Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin (CIG)
C07K 14/785
. .
Alveolar surfactant peptides ; Pulmonary surfactant peptides
C07K 14/79
. .
Transferrins, e.g. lactoferrins, ovotransferrins
Collapse
C07K 14/795
.
Porphyrin- or corrin-ring-containing peptides
C07K 14/80
. .
Cytochromes
C07K 14/805
. .
Haemoglobins ; Myoglobins
Collapse
C07K 14/81
.
Protease inhibitors
C07K 14/8103
. .
{
Exopeptidase (E.C. 3.4.11-19) inhibitors
}
Collapse
C07K 14/8107
. .
{
Endopeptidase (E.C. 3.4.21-99) inhibitors
}
Collapse
C07K 14/811
. . .
{
Serine protease (E.C. 3.4.21) inhibitors
}
Collapse
C07K 14/8114
. . . .
{
Kunitz type inhibitors
}
C07K 14/8117
. . . . .
{
Bovine/basic pancreatic trypsin inhibitor ( BPTI, aprotinin )
}
Collapse
C07K 14/8121
. . . .
{
Serpins
}
C07K 14/8125
. . . . .
{
Alpha-1-antitrypsin
}
C07K 14/8128
. . . . .
{
Antithrombin III
}
C07K 14/8132
. . . . .
{
Plasminogen activator inhibitors
}
C07K 14/8135
. . . .
{
Kazal type inhibitors, e.g. pancreatic secretory inhibitor, ovomucoid
}
C07K 14/8139
. . .
{
Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
}
C07K 14/8142
. . .
{
Aspartate protease (E.C. 3.4.23) inhibitors, e.g. HIV protease inhibitors
}
C07K 14/8146
. . .
{
Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
}
C07K 14/815
. .
from leeches, e.g. hirudin, eglin
C07K 14/82
.
Translation products from oncogenes
C07K 14/825
.
Metallothioneins
Collapse
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
{
( antibodies with enzymatic activity, e.g. abzymes C12N 9/0002 )
}
NOTE
-
Documents characterised by the technical aspects of the construction of an antibody or fragment thereof, should be classified in C07K 16/00 to C07K 16/065 or C07K 16/46 to C07K 16/468

Documents not characterised by the technical aspects of the construction of an antibody or fragment thereof, should be classified only according to their specificity, where necessary accompanied by one or more appropriate indexing codes

C07K 16/005
.
{
constructed by phage libraries
}
C07K 16/02
.
from eggs
C07K 16/04
.
from milk
Collapse
C07K 16/06
.
from serum
C07K 16/065
. .
{
Purification, fragmentation
}
Collapse
C07K 16/08
.
against material from viruses
Collapse
C07K 16/081
. .
{
from DNA viruses
}
C07K 16/082
. . .
{
Hepadnaviridae, e.g. hepatitis B virus
}
C07K 16/084
. . .
{
Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
}
Collapse
C07K 16/085
. . .
{
Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
}
C07K 16/087
. . . .
{
Herpes simplex virus
}
C07K 16/088
. . . .
{
Varicella-zoster virus, e.g. cytomegalovirus
}
Collapse
C07K 16/10
. .
from RNA viruses,
{
e.g. hepatitis E virus
}
C07K 16/1009
. . .
{
Picornaviridae, e.g. hepatitis A virus
}
C07K 16/1018
. . .
{
Orthomyxoviridae, e.g. influenza virus
}
C07K 16/1027
. . .
{
Paramyxoviridae, e.g. respiratory syncytial virus
}
Collapse
C07K 16/1036
. . .
{
Retroviridae, e.g. leukemia viruses
}
Collapse
C07K 16/1045
. . . .
{
Lentiviridae, e.g. HIV, FIV, SIV
}
C07K 16/1054
. . . . .
{
gag-pol, e.g. p17, p24
}
C07K 16/1063
. . . . .
{
env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
}
C07K 16/1072
. . . . .
{
Regulatory proteins, e.g. tat, rev, vpt
}
Collapse
C07K 16/1081
. . .
{
Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
}
C07K 16/109
. . . .
{
Hepatitis C virus; Hepatitis G virus
}
Collapse
C07K 16/12
.
against material from bacteria
Collapse
C07K 16/1203
. .
{
from Gram-negative bacteria
}
C07K 16/1207
. . .
{
from Spirochaetales (O), e.g. Treponema, Leptospira
}
C07K 16/121
. . .
{
from Helicobacter (Campylobacter) (G)
}
C07K 16/1214
. . .
{
from Pseudomonadaceae (F)
}
C07K 16/1217
. . .
{
from Neisseriaceae (F), e.g. Acinetobacter
}
C07K 16/1221
. . .
{
from Brucella (G)
}
C07K 16/1225
. . .
{
from Bordetella (G)
}
Collapse
C07K 16/1228
. . .
{
from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
}
C07K 16/1232
. . . .
{
from Escherichia (G)
}
C07K 16/1235
. . . .
{
from Salmonella (G)
}
C07K 16/1239
. . .
{
from Vibrionaceae (G)
}
C07K 16/1242
. . .
{
from Pasteurellaceae (F), e.g. Haemophilus influenza
}
C07K 16/1246
. . .
{
from Rickettsiales (O)
}
C07K 16/125
. . .
{
from Chlamydiales (O)
}
C07K 16/1253
. . .
{
from Mycoplasmatales, e.g. Pleuropneumonia-like organisms (PPLO)
}
C07K 16/1257
. . .
{
from Bacteridaceae (F)
}
C07K 16/126
. . .
{
from Legionella (G)
}
C07K 16/1264
. . .
{
from Rhizobiaceae (F)
}
Collapse
C07K 16/1267
. .
{
from Gram-positive bacteria
}
C07K 16/1271
. . .
{
from Micrococcaceae (F), e.g. Staphylococcus
}
C07K 16/1275
. . .
{
from Streptococcus (G)
}
C07K 16/1278
. . .
{
from Bacillus (G)
}
C07K 16/1282
. . .
{
from Clostridium (G)
}
C07K 16/1285
. . .
{
from Corynebacterium (G)
}
C07K 16/1289
. . .
{
from Mycobacteriaceae (F)
}
C07K 16/1292
. . .
{
from Actinomyces; from Streptomyces (G)
}
C07K 16/1296
. . .
{
from Listeria
}
C07K 16/14
.
against material from fungi, algea or lichens
C07K 16/16
.
against material from plants
Collapse
C07K 16/18
.
against material from animals or humans
Collapse
C07K 16/20
. .
from protozoa
C07K 16/205
. . .
{
Plasmodium
}
C07K 16/22
. .
against growth factors;
{
against growth regulators
}
Collapse
C07K 16/24
. .
against cytokines, lymphokines or interferons
Collapse
C07K 16/241
. . .
{
Tumor Necrosis Factors
}
C07K 16/242
. . . .
{
Lymphotoxin (LT)
}
C07K 16/243
. . .
{
Colony Stimulating Factors
}
Collapse
C07K 16/244
. . .
{
Interleukins (IL)
}
C07K 16/245
. . . .
{
IL-1
}
C07K 16/246
. . . .
{
IL-2
}
C07K 16/247
. . . .
{
IL-4
}
C07K 16/248
. . . .
{
IL-6
}
C07K 16/249
. . .
{
Interferons
}
C07K 16/26
. .
against hormones;
{
against hormone releasing or inhibiting factors
}
Collapse
C07K 16/28
. .
against receptors, cell surface antigens or cell surface determinants
Collapse
C07K 16/2803
. . .
{
against the immunoglobulin superfamily
}
C07K 16/2806
. . . .
{
against CD2
}
C07K 16/2809
. . . .
{
against the T-cell receptor (TcR)-CD3 complex
}
C07K 16/2812
. . . .
{
against CD4
}
C07K 16/2815
. . . .
{
against CD8
}
C07K 16/2818
. . . .
{
against CD28 or CD152
}
C07K 16/2821
. . . .
{
against ICAM molecules, e.g. CD50, CD54, CD102
}
C07K 16/2824
. . . .
{
against CD58
}
C07K 16/2827
. . . .
{
against B7 molecules, e.g. CD80, CD86
}
C07K 16/283
. . . .
{
against Fc-receptors, e.g. CD16, CD32, CD64 ( CD23 C07K 16/2851 )
}
C07K 16/2833
. . . .
{
against MHC-molecules, e.g. HLA-molecules
}
C07K 16/2836
. . . .
{
against CD106
}
Collapse
C07K 16/2839
. . .
{
against the integrin superfamily
}
C07K 16/2842
. . . .
{
against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
}
C07K 16/2845
. . . .
{
against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
}
C07K 16/2848
. . . .
{
against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
}
Collapse
C07K 16/2851
. . .
{
against the lectin superfamily, e.g. CD23, CD72
}
C07K 16/2854
. . . .
{
against selectins, e.g. CD62
}
C07K 16/2857
. . .
{
against nuclear receptors, e.g. retinoic acid receptor (RAR), RXR, orphan receptor
}
C07K 16/286
. . .
{
against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
}
C07K 16/2863
. . .
{
against receptors for growth factors, growth regulators
}
C07K 16/2866
. . .
{
against receptors for cytokines, lymphokines, interferons
}
C07K 16/2869
. . .
{
against hormone receptors ( for antibodies against neuromediator receptors C07K 16/286 )
}
C07K 16/2872
. . .
{
against prion molecules, e.g. CD230
}
C07K 16/2875
. . .
{
against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 ( against NGF C07K 16/22 , against TNF C07K 16/241 )
}
C07K 16/2878
. . .
{
against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
}
C07K 16/2881
. . .
{
against CD71
}
C07K 16/2884
. . .
{
against CD44
}
C07K 16/2887
. . .
{
against CD20
}
C07K 16/289
. . .
{
against CD45
}
C07K 16/2893
. . .
{
against CD52
}
C07K 16/2896
. . .
{
against molecules with a "CD"-designation, not provided for elsewhere
}
Collapse
C07K 16/30
. . .
from tumour cells
C07K 16/3007
. . . .
{
Carcino-embryonic Antigens
}
C07K 16/3015
. . . .
{
Breast
}
C07K 16/3023
. . . .
{
Lung
}
C07K 16/303
. . . .
{
Liver or Pancreas
}
C07K 16/3038
. . . .
{
Kidney, bladder
}
C07K 16/3046
. . . .
{
Stomach, Intestines
}
C07K 16/3053
. . . .
{
Skin, nerves, brain
}
C07K 16/3061
. . . .
{
Blood cells
}
C07K 16/3069
. . . .
{
Reproductive system, e.g. ovaria, uterus, testes, prostate
}
Collapse
C07K 16/3076
. . . .
{
against structure-related tumour-associated moieties
}
C07K 16/3084
. . . . .
{
against tumour-associated gangliosides
}
C07K 16/3092
. . . . .
{
against tumour-associated mucins
}
C07K 16/32
. .
against translation products of oncogenes
C07K 16/34
. .
against blood group antigens
C07K 16/36
. .
against blood coagulation factors
C07K 16/38
.
against protease inhibitors of peptide structure
C07K 16/40
.
against enzymes
Collapse
C07K 16/42
.
against immunoglobulins
Collapse
C07K 16/4208
. .
{
against an idiotypic determinant on Ig
}
Collapse
C07K 16/4216
. . .
{
against anti-viral Ig
}
C07K 16/4225
. . . .
{
against anti-HIV Ig
}
C07K 16/4233
. . .
{
against anti-bacterial Ig
}
Collapse
C07K 16/4241
. . .
{
against anti-human or anti-animal Ig
}
C07K 16/425
. . . .
{
against anti-protozoal Ig
}
Collapse
C07K 16/4258
. . . .
{
against anti-receptor Ig
}
C07K 16/4266
. . . . .
{
against anti-tumor receptor Ig
}
C07K 16/4275
. . . . .
{
against anti-CD4 Ig
}
Collapse
C07K 16/4283
. .
{
against an allotypic or isotypic determinant on Ig
}
C07K 16/4291
. . .
{
against IgE
}
C07K 16/44
.
against material not provided for elsewhere,
{
e.g. haptens, metals, DNA, RNA, amino acids
}
Collapse
C07K 16/46
.
Hybrid immunoglobulins ( hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K 19/00 )
Collapse
C07K 16/461
. .
{
Igs containing Ig-regions, -domains or -residues form different species
}
C07K 16/462
. . .
{
Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
}
Collapse
C07K 16/464
. . .
{
Igs containing CDR-residues from one specie grafted between FR-residues from another
}
C07K 16/465
. . . .
{
with additional modified FR-residues
}
C07K 16/467
. . .
{
Igs with modifications in the FR-residues only
}
C07K 16/468
. .
{
Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
}
Collapse
Carrier-bound or immobilised peptides ( carrier-bound or immobilised enzymes C12N 11/00 ) ; Preparation thereof
Collapse
C07K 17/02
.
Peptides being immobilised on, or in, an organic carrier
C07K 17/04
. .
entrapped within the carrier, e.g. gel, hollow fibre
C07K 17/06
. .
attached to the carrier via a bridging agent
C07K 17/08
. .
the carrier being a synthetic polymer
Collapse
C07K 17/10
. .
the carrier being a carbohydrate
C07K 17/12
. . .
Cellulose or derivatives thereof
C07K 17/14
.
Peptides being immobilised on, or in, an inorganic carrier
Hybrid peptides
C07K 2299/00
Coordinates from 3D structures of peptides, e.g. proteins or enzymes
Collapse
C07K 2316/00
Immunoglobulins specific feautures
Collapse
C07K 2316/50
.
Immunoglobulins characterised by their fragments
C07K 2316/52
. .
Constant or Fc region
C07K 2316/95
.
Antibodies with agonistic, e.g. apoptotic, activity upon their specific binding to an antigen
C07K 2316/96
.
Antibodies with antagonisticactivity upon their specific binding to an antigen
Collapse
C07K 2317/00
Immunoglobulins specific feautures
Collapse
C07K 2317/10
.
characterized by their source of isolation or production
C07K 2317/11
. .
isolated from eggs
C07K 2317/12
. .
isolated from milk
C07K 2317/13
. .
isolated from plants
C07K 2317/14
. .
Specific host cells or culture conditions, e.g. components, pH or temperature
Collapse
C07K 2317/20
.
characterized by taxonomic origin
C07K 2317/21
. .
from primates, e.g. man
C07K 2317/22
. .
from camelids, e.g. camel, llama or dromedary
C07K 2317/23
. .
from birds
C07K 2317/24
. .
containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Collapse
C07K 2317/30
.
characterized by aspects of specificity or valency
C07K 2317/31
. .
multispecific
C07K 2317/32
. .
specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
C07K 2317/33
. .
Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
C07K 2317/34
. .
Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
C07K 2317/35
. .
Valency
Collapse
C07K 2317/40
.
characterized by post-translational modification
C07K 2317/41
. .
Glycosylation, sialylation, or fucosylation
Collapse
C07K 2317/50
.
characterized by immunoglobulin fragments
C07K 2317/51
. .
Complete heavy chain or Fd fragment, i.e. VH + CH1
C07K 2317/515
. .
Complete light chain, i.e. VL + CL
Collapse
C07K 2317/52
. .
Constant or Fc region ; Isotype
C07K 2317/522
. . .
CH1 domain
C07K 2317/524
. . .
CH2 domain
C07K 2317/526
. . .
CH3 domain
C07K 2317/528
. . .
CH4 domain
C07K 2317/53
. . .
Hinge
C07K 2317/54
. .
F(ab')2
C07K 2317/55
. .
Fab or Fab'
Collapse
C07K 2317/56
. .
variable (Fv) region , i.e. VH and/or VL
C07K 2317/565
. . .
Complementarity determining region (CDR)
C07K 2317/567
. . .
Framework region (FR)
C07K 2317/569
. . .
Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
Collapse
C07K 2317/60
.
characterized by non-natural combinations of immunoglobulin fragments
Collapse
C07K 2317/62
. .
comprising only variable region components
C07K 2317/622
. . .
Single chain antibody (scFv)
C07K 2317/624
. . .
Disulfide-stabilized antibody (dsFv)
C07K 2317/626
. . .
Diabody or triabody
C07K 2317/64
. .
comprising a combination of variable region and constant region components
C07K 2317/66
. .
comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
Collapse
C07K 2317/70
.
characterized by effect upon binding to a cell or to an antigen
C07K 2317/71
. .
Decreased effector function due to an Fc-modification
C07K 2317/72
. .
Increased effector function due to an Fc-modification
Collapse
C07K 2317/73
. .
Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
C07K 2317/732
. . .
Antibody-dependent cellular cytotoxicity (ADCC)
C07K 2317/734
. . .
Complement-dependent cytotoxicity (CDC)
C07K 2317/74
. .
Inducing cell proliferation
C07K 2317/75
. .
Agonist effect on antigen
C07K 2317/76
. .
Antagonist effect on antigen, e.g. neutralization or inhibition of binding
C07K 2317/77
. .
Internalization into the cell
Collapse
C07K 2317/80
.
remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
C07K 2317/81
. .
functional in the endoplasmatic reticulum (ER) or the Golgi apparatus
C07K 2317/82
. .
functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria
Collapse
C07K 2317/90
.
characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
C07K 2317/92
. .
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
C07K 2317/94
. .
Stability, e.g. half-life, pH, temperature or enzyme-resistance
Collapse
C07K 2318/00
Antibody mimetics or scaffolds
C07K 2318/10
.
Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
C07K 2318/20
.
Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
Collapse
C07K 2319/00
Fusion polypeptide
Collapse
C07K 2319/01
.
containing a localisation/targetting motif
C07K 2319/02
. .
containing a signal sequence
C07K 2319/03
. .
containing a transmembrane segment
C07K 2319/033
. .
containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
C07K 2319/034
. .
containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
C07K 2319/035
. .
containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
C07K 2319/036
. .
targeting to the medium outside of the cell, e.g. type III secretion
C07K 2319/04
. .
containing an ER retention signal such as a C-terminal HDEL motif
C07K 2319/05
. .
containing a GOLGI retention signal
C07K 2319/055
. .
containing a signal for localisation to secretory granules ( for exocytosis )
C07K 2319/06
. .
containing a lysosomal/endosomal localisation signal
C07K 2319/07
. .
containing a mitochondrial localisation signal
C07K 2319/08
. .
containing a chloroplats localisation signal
C07K 2319/09
. .
containing a nuclear localisation signal
C07K 2319/095
. .
containing a nuclear export signal
C07K 2319/10
. .
containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Collapse
C07K 2319/20
.
containing a tag with affinity for a non-protein ligand
C07K 2319/21
. .
containing a His-tag
C07K 2319/22
. .
containing a Strep-tag
C07K 2319/23
. .
containing a GST-tag
C07K 2319/24
. .
containing a MBP ( maltose binding protein ) -tag
C07K 2319/30
.
Non-immunoglobulin-derived peptide or protein having an imunoglobulin constant or Fc region, or a fragment thereof, attached thereto
C07K 2319/31
.
fusions, other than Fc, for prolonged plasma life, e.g. albumin
C07K 2319/32
.
fusions with soluble part of a cell surface receptor, "decoy receptors"
C07K 2319/33
.
fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
C07K 2319/35
.
containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
Collapse
C07K 2319/40
.
containing a tag for immunodetection, or an epitope for immunisation
C07K 2319/41
. .
containing a Myc-tag
C07K 2319/42
. .
containing a HA(hemagglutinin)-tag
C07K 2319/43
. .
containing a FLAG-tag
C07K 2319/50
.
containing protease site
C07K 2319/55
.
containing a fusion with a toxin, e.g. diphteria toxin
C07K 2319/60
.
containing spectroscopic/fluorescent detection, e.g. green fluorescent protein (GFP)
C07K 2319/61
.
containing an enzyme fusion for detection ( lacZ, luciferase )
Collapse
C07K 2319/70
.
containing domain for protein-protein interaction
C07K 2319/705
. .
containing a protein-A fusion
Collapse
C07K 2319/71
. .
containing domain for transcriptional activaation, e.g. VP16
C07K 2319/715
. . .
containing a domain for ligand dependent transcriptional activation, e.g. containing a steroid receptor domain
C07K 2319/72
. .
containing SH2 domain
C07K 2319/73
. .
containing coiled-coiled motif ( leucine zippers )
C07K 2319/735
. .
containing a domain for self-assembly, e.g. a viral coat protein ( includes phage display )
Collapse
C07K 2319/74
. .
containing a fusion for binding to a cell surface receptor
C07K 2319/75
. . .
containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Collapse
C07K 2319/80
.
containing a DNA binding domain, e.g. Lacl or Tet-repressor
C07K 2319/81
. .
containing a Zn-finger domain for DNA binding
C07K 2319/85
.
containing an RNA binding domain
Collapse
C07K 2319/90
.
containing a motif for post-translational modification
Collapse
C07K 2319/91
. .
containing a motif for glycosylation
C07K 2319/912
. . .
containing a GPI (phosphatidyl-inositol glycane) anchor
C07K 2319/915
. .
containing a motif for acylation
C07K 2319/92
. .
containing an intein ( "protein splicing" ) domain
C07K 2319/95
.
containing a motif/fusion for degradation ( ubiquitin fusions, PEST sequence )
This page is owned by Office of Patent Classification.
Last Modified: 10/10/2013